Atavistik Bio
Harnessing the power of allostery to develop transformative medicines
Cambridge, United States · Founded 2021 · $225.3M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- atavistikbio.com
- Total Funding
- $225.3M
- Last Round
- $40.0M Extension RoundMar 2026
- Rounds
- 4
About
Atavistik Bio is a clinical-stage biotechnology company developing novel allosteric small molecule therapeutics for rare hematological disorders and cancers. Its lead asset ATV-1601 is an oral allosteric AKT1-selective inhibitor targeting Hereditary Hemorrhagic Telangiectasia, which received FDA IND clearance and Fast Track designation in 2026. The company also advances a JAK2 V617F mutant-selective inhibitor for myeloproliferative neoplasms.
Summary
Atavistik Bio is a Biotech company based in Cambridge, United States, founded in 2021. It has raised $225.3M in total across 4 rounds, most recently a $40.0M Extension Round round in Mar 2026. Investors include Lux Capital, Nextech Invest and The Column Group.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2026
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...